Speaker Profile
PhD, Global Head of Business Development and Customer Solutions, biomodal
Biography
Dr. Jennifer Stone is a commercial life sciences executive specializing in building markets, high performing international teams and sustainable topline growth. She joined biomodal in 2023 to build out and lead the business development, sales and customer solutions teams to deliver on the companys commercial growth objectives. Dr. Stone has over two decades of experience in the omics space. Before joining biomodal, Dr. Stone worked at PacBio as part of the leadership team that led to transformative change within that organization and ultimately the launch of the game changing Revio long read sequencing platform. She also held several commercial roles at Illumina. Dr. Stone has focused her career on the intersection of technology and precision health, specifically with early mid stage technologies as they cross the chasm into translational and applied use.
Talk
Refining Liquid Biopsy: Generating More Info From Cell-Free DNA
Liquid biopsy for profiling cell-free DNA holds promise to transform how we manage cancer by early detection and identification of residual disease and subtype. biomodals duet multiomics solution +modC generates data from low input amounts, obtains more sensitive somatic variant calling, and obtains multimodal information to discriminate cancer patients from healthy controls.
Clinical Dx Showcase:
biomodal
biomodal (previously Cambridge Epigenetix) is an omics-based life sciences technology and analytics company developing products that bring biological dynamism into focus.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
